Researchers have a bold new strategy for beating the dreaded disease: stop it before it starts
THE ANNOUNCEMENT came the day before Thanksgiving, but there was nothing in it to be thankful for: An experimental Alzheimer’s drug many thought would slow the disease’s steady cognitive decline had failed to make a significant difference in a massive trial of people with early signs of the illness.
Marty Reiswig took the news hard. “I was just sad,” he says. “I was really hopeful that it would be life-changing for us.” Reiswig doesn’t have Alzheimer’s disease—he’s a 38-year-old real estate agent in good health. But he is part of a large extended family that’s been afflicted by Alzheimer’s for generations. His Uncle Roy died of the disease. So did Grandpa Ralph. Eleven great-aunts and great-uncles. Dozens of cousins. And now, Reiswig says, “I’ve got a 64-year old father who’s almost dead of Alzheimer’s.”
His family is one of around 500 in the world with a genetic mutation that means its carriers will develop Alzheimer’s at a much younger age than those without the mutation, for whom the age of onset is typically about 80. For the Reiswigs, those with the gene become sick around their 50th birthday. Other high risk families can start showing symptoms as early as their mid-30s or, in some cases, their late 20s.
Reiswig decided not to learn his own gene status— there’s a 50-50 chance he inherited his father’s faulty DNA, and he prefers living with the uncertainty. However, he isn’t just idly waiting to meet his fate. Three years ago, he signed up for an innovative drug study that could alter his family’s genetic destiny. Once a month, a nurse comes to his home, inserts a needle in his arm and watches as a bag full of liquid slowly drips into his bloodstream.
This story is from the February 24 2017 edition of Newsweek.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the February 24 2017 edition of Newsweek.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ramy Youssef
DESCRIBING RAMY YOUSSEF'S WORK ISN'T EASY, BECAUSE HE REFUSES TO settle on just one thing. \"I feel really inspired to connect in the way that it makes sense.\"
Tobias Menzies
HOW MUCH DO WE REALLY KNOW ABOUT THE assassination of President Abraham Lincoln? That's a question Tobias Menzies hopes to answer in Apple TV+'s Manhunt (March 15).
The Fall and Rise of Katt Williams
He's had a string of run-ins with the law, yet the comedian's popularity continues to grow-with a recent podcast appearance blowing up the internet
AMERICA'S Greatest Workplaces for JOB STARTERS 2024
Getting a career started is never easy. First-day stumbling blocks can give way to larger questions about choosing the right career path. Imposter syndrome, information overload, the challenge of new colleagues: it's almost enough to make you miss the routine of sending out endless résumés to online job descriptions.
THE INCONCEIVABLE SEARCH FOR SPERM
Making MOTHERHOOD a reality in the face of virtually every cultural taboo
I'm Suing Harvard Over Rife Antisemitism
I applied to the university's Divinity School to be an ambassador for Orthodox Jews and build bridges with other cultures; instead I'm battling discrimination
Gen Z's Pockets Full of Cash
Digital wallets and bank cards might appear to be the modern way to pay, but physical money is making a comeback among young adults
Biden's Age Problem Tears Democrats Apart
After being depicted as an 'elderly man with a poor memory,' questions surrounding the president's advanced years are dividing his party
Country Has Won Our Achy Breaky Hearts
The genre has never been so popular-and with the likes of Beyoncé reminding fans of its roots, its mainstream appeal looks set to grow and grow
'Deadly Risk' of Fat-Loss Drugs
Diabetes treatment Ozempic has become popular among dieters due to its weightloss side effect, but a study warns of a link between the drug and suicidal thoughts